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Purpose: Coding variants in the optineurin gene (OPTN, GLC1E) have been reported to play a role in primary open-angle
glaucoma (POAG) in various populations. This study investigated the role of OPTN sequence variants in patients with
POAG in Ghana (West Africa).
Methods: This is a case-control study of unrelated Ghanaian POAG cases and non-glaucomatous controls. Ascertainment
criteria for POAG included the presence of glaucomatous optic nerve neuropathy, associated visual field loss, and elevated
intraocular pressure (IOP) in both eyes, all in the absence of secondary causes of glaucoma. Controls had normal optic
nerves, visual fields, and IOP. All the coding exons of OPTN were polymerase chain reaction (PCR) amplified and
sequenced in all 140 cases and 130 controls using an ABI 3730 DNA analyzer.
Results: All the coding exons of OPTN were sequenced in 140 POAG patients and 130 controls. Several coding variants
were identified including M98K, A134A, V147L, P292P, A301G, S321S, and E322K. Three coding variants (V147L,
P292P, and A301G) have not been reported previously. There were no significant differences on the frequencies of all
the identified variants between POAG cases and controls in this population.
Conclusions: This is the first comprehensive study of OPTN in a single West African population. Our results suggest that
coding variants in OPTN may not contribute to the risk for POAG in persons of West African descent.
Glaucoma  is  a  group  of  disorders  defined  by  a
characteristic loss of retinal ganglion cells associated with
optic nerve degeneration and visual field loss. It is the second
leading cause of bilateral blindness worldwide [1]. Primary
open-angle glaucoma (POAG, OMIM 137760) is the most
common  form  of  glaucoma  in  the  United  States  and
worldwide, afflicting approximately 67 million individuals in
the year 2000 alone [1]. Well recognized risk factors for the
development of POAG include elevated intraocular pressure
(IOP), positive family history of glaucoma, refractive error,
and race; African-Americans have a higher risk of developing
POAG [1-3].
There is a strong hereditary component to glaucoma as
first-degree relatives of affected individuals have a 7–10 fold
higher  risk  of  developing  the  disease  than  the  general
population [4]. Using genetic linkage analysis, at least 14
chromosomal loci for POAG (GLC1A- GLC1N) have been
identified in family data sets and are listed by HUGO (Human
Genome  Organization,  Geneva,  Switzerland).  Disease-
associated  sequence  variants  in  three  genes,  myocilin
(MYOC,  GLC1A),  optineurin  (OPTN,  GLC1E),  and  WD
repeat domain 36 (WDR36, GLC1G), have been described in
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POAG and other types of glaucoma [5-7]. Disease-associated
mutations of myocilin are generally associated with a juvenile
or early-adult form of POAG, which account for about 3%–
5% of POAG patients.
The mechanistic role of OPTN in the pathogenesis of
glaucoma remains unclear. It is widely expressed in both
ocular and non-ocular tissues including but not limited to the
heart,  brain,  placenta,  liver,  skeletal  muscle,  kidney,  and
pancreas. In ocular tissues, it is expressed in the trabecular
meshwork,  non-pigmented  ciliary  epithelium,  retina,
Schlemm's canal, and the aqueous humor [8]. The OPTN
protein interacts with different proteins that are involved in
apoptosis, inflammation, and vasoconstriction [8,9]. OPTN
might play a neuroprotective role by reducing retinal ganglion
cell susceptibility to apoptosis [8,9]. Overexpression of OPTN
blocks  cytochrome  c  release  from  the  mitochondria  and
protects the cell from hydrogen peroxide-induced cell death
[10]. It was also found that OPTN negatively regulates TNF-
α induced NF-κB activation, leading to reduced apoptosis [9,
11]. OPTN was originally identified as a dominant, normal
tension glaucoma (NTG) gene in a large study involving 54
families [6]. These sequence variants (E50K, M98K, R545Q,
and  c691–692insAG)  in  OPTN  were  considered  disease
causing in the original study [6]. The variant, E50K, remains
the most consistently found in association studies with normal
tension  glaucoma.  It  is  found  that  OPTN  E50K  increases
binding to TANK-binding kinase 1 (TBK1), which forms a
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2367complex to regulate TNF-α and its pro-apoptotic effects [12].
OPTN  sequence  variations  have  also  been  shown  to  be
associated with POAG in Indian and Japanese populations
[13,14]  while  playing  a  much  less  significant  role  in
Caucasians [15-18].
African-American ancestry is estimated to increase the
risk of POAG by fourfold to sixfold when compared with
European  ancestry  [19].  African-Americans  are  largely
descended from ancestors in West Africa. We have previously
shown that POAG in Ghana has an earlier age of onset and
appears to be more clinically severe than in the United States
and Europe [20]. POAG patients with mutations in myocilin
have  a  similar  phenotype.  In  an  earlier  investigation,  we
reported that myocilin mutations cause approximately 4% of
POAG in West Africa [21,22]. This report investigates the role
of OPTN coding variants in POAG cases and controls in the
same West African population from Ghana.
METHODS
Subjects: This study adhered to the tenets of the Declaration
of  Helsinki.  Informed  consent  was  obtained  from  all
participating individuals after explanation of the nature and
possible  consequences  of  the  study.  The  research  was
reviewed and approved by the institutional review boards of
all  participating  institutions  including  Duke  University
Medical Center (Durham, NC) and the Ghana Ministry of
Health (Accra, Ghana).
Clinical  data  and  DNA  samples  were  collected  from
individuals  identified  with  POAG  and  unaffected  family
members from Ghana. All POAG cases and controls were
enrolled from either private clinics or the University of Ghana
in Accra, the capital of this country. All patients recruited for
the study were screened and ascertained by fellowship-trained
glaucoma subspecialists (P.C., L.W.H., or R.R.A.). POAG
subjects were unrelated and met the following three inclusion
criteria:  (1)  intraocular  pressure  (IOP;  by  applanation
tonometry)  greater  than  22  mmHg  in  both  eyes  without
medications  or  greater  than  19  mmHg  on  two  or  more
medications; (2) glaucomatous optic neuropathy in both eyes;
and (3) visual field loss consistent with optic nerve damage in
at least one eye [23]. Glaucomatous optic nerve damage was
defined as a vertical cup-to-disc ratio higher than 0.7 or a focal
loss of the nerve fiber layer (notch), which is associated with
a consistent glaucomatous visual field defect. Visual fields
were performed using standard automated perimetry [1]. An
open anterior chamber angle has been found in all of our
POAG cases. Exclusion criteria included the presence of any
secondary form of glaucoma including exfoliation syndrome
or a history of ocular trauma. The criteria for unrelated control
subjects were (1) no first degree relative with glaucoma; (2)
intraocular pressure less than 22 mmHg tested by applanation
tonometry on two occasions; (3) no evidence of glaucomatous
optic neuropathy; and (4) normal visual field by automated
perimetry or frequency doubling test (FDT).
DNA analysis: Genomic DNA was extracted from peripheral
blood by standard techniques (Gentra, Minneapolis, MN).
Primers flanking each coding exon (exon 4−16) in OPTN were
designed with Primer3 software [24] and were listed in Table
1. All sequencing was performed using appropriately selected
primers  and  conditions  optimized  in  a  standard  fashion.
Platinum Taq DNA polymerase (Invitrogen, Carlsbad, CA)
was used for all the polymerase chain reactions (PCRs). The
PCRs  were  performed  in  MJ  Research  PTC-200  PCR
machines (MJ Research, Waltham, MA) using a touchdown
program (94 °C 3 min; then 94 °C 30 s, 65 °C 30 s, 72 °C 30
s for two cycles; 94 °C 30 s, 63 °C 30 s, 72 °C 30 s for two
cycles; 94 °C 30 s, 61 °C 30 s, 72 °C 30 s for two cycles; 94 °C
30 s, 59 °C 30 s, 72 °C 30 s for two cycles; 94 °C 30 s, 57 °C
30 s, 72 °C 30 s for two cycles; 94 °C 30 s, 55 °C 30 s, 72 °C
30 s for 30 cycles; and 72 °C 3 min). Sequencing reactions
were  performed  using  BigDye®  Terminator  v3.1  Cycle
Sequencing Kits (Applied Biosystems, Foster City, CA) and
run on the ABI 3730 DNA analyzer (Applied Biosystems).
All the sequence analysis was done by using the Sequencher
4.8 (Gene Codes, Ann Arbor, MI). All suspected variations
were  confirmed  by  bidirectional  sequencing.  The  M98K
variant was subsequently genotyped using a custom TaqMan
SNP (single nucleotide polymorphism) Genotyping Assay
(Applied  Biosystems).  The  E322K  variant  could  not  be
genotyped by TaqMan SNP genotyping due to the lack of
available assay from ABI (Applied Biosystems).
Statistical  analysis:  Sequencing  data  were  analyzed  as
mentioned previously [25,26]. Briefly, allele frequencies for
each  coding  variant  in  POAG  cases  and  controls  were
compared by logistic regression with adjustment for age and
sex (SAS software; SAS Institute Inc., Cary, NC). Analysis
of the Hardy–Weinberg equilibrium (HWE) was performed
separately for patients and controls using GDA (Genetic Data
Analysis)  software  according  to  previously  described
methods [25]. SNP genotypes were coded according to a log-
additive model in which the relative risk for carriers of two
variant (minor) alleles when compared with the reference
group (homozygous wild-type) was assumed to be the square
of the relative risk for carriers of one variant. A p value less
than 0.05 was considered statistically significant.
RESULTS
DNA  and  relevant  clinical  data  were  collected  from  140
POAG cases and 130 controls. Detailed information about this
data set has been described previously [25,26]. Briefly, the
mean ages for POAG cases and controls were 63±12.6 years
old and 59.4±12.6 years old, respectively. The percentages of
POAG cases and controls that were female were 50% and
57%,  respectively.  The  mean  IOPs  for  POAG  cases  and
controls  were  33.6±11.1  mmHg  and  17.2±2.8  mmHg,
respectively.
Seven coding variants were identified in OPTN in this
data set. There were three synonymous (A134A, P292P, and
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2368S321S) and four non-synonymous (M98K, V147L, A301G,
and E322K) coding variants (Table 2). The M98K, A134A,
S321S,  and  E322K  variants  have  been  reported  in  other
populations [6,15,16,27-30]. The other three coding variants
(V147L, P292P, and A301G) are novel and have not been
previously reported. The M98K variant in exon 5 was detected
in 43 cases (two homozygotes and 41 heterozygotes) and 33
controls (two homozygotes and 31 heterozygotes; p>0.05).
One individual with POAG had a novel V147L variation in
exon 6 as a heterozygote. The age-onset for this patient was
59 years old. Another POAG patient whose age-onset was
relative early at the age of 40 years had a novel A301G variant
in exon 10 as a heterozygote. None of the controls exhibited
either of these two sequence variants. However, neither of
these variants showed any statistically significant difference
in  allele  frequencies  between  cases  and  controls  (p>0.05;
Table  3).  Seven  POAG  patients  and  one  control  had  the
heterozygous E322K variant in exon 10. These seven patients
have relatively high IOP (>30 mmHg). However, the allele
frequency of this variant is not significantly different between
POAG cases and controls (p>0.05). None of the remaining
synonymous coding variants (A134A, P292P, and S321S)
showed  significantly  different  allele  frequencies  between
POAG cases and controls. No HWE problem was detected for
any of the coding variants in OPTN (p>0.05).
TABLE 2. OPTN DNA SEQUENCE VARIANTS IN GHANA POAG PATIENTS.
Location Sequence change Codon change SNP ID
Exon 5 c.603A>T M98K rs11258194
Exon 6 c.712C>A A134A
Exon 6 c.749G>C V147L
Exon 9 c.1186G>A P292P
Exon 10 c.1212C>G A301G
Exon 10 c.1273C>T S321S
Exon 10 c.1274G>A E322K rs523747
Nucleotides are numbered as in GenBank AF420371.
DISCUSSION
In this study, we report the contribution of OPTN variants in
POAG cases in Ghana. We found a total of seven OPTN
coding variants, four of which were non-synonymous and
three were synonymous coding variants. Of these variants,
three have not been previously reported. The large number of
novel OPTN variants is likely due to two factors. First, our
study  is  the  first  comprehensive  study  to  examine  the
sequencing variants of OPTN in a single western African
population. Second, African populations may have greater
genetic diversity compared with the non-African populations
reported to date [31,32]. The African populations arise from
ancient  and  recent  population  expansion  and  contraction,
short and long range migrations, and population admixture.
The  genetic  association  between  OPTN  variants  and
glaucoma  has  been  extensively  studied  in  different
populations. Mutations in OPTN account for about 16% of
familial  POAG  with  normal  tension  in  the  original  study
[33]. These sequence variants (M98K, E50K, R545Q, and
c691–692insAG) were considered disease-causing originally
[6]. E50K has been consistently confirmed by many studies
as disease-causing [8,9,33]. R545Q has not been confirmed in
other  populations  [9,33].  Other  variants  have  also  been
reported in POAG patients including T34T, E163E, 553–5C,
and E322K [9,28,34].
Coding  variant,  E322K  (rs523747),  was  found  to  be
present in more POAG cases than controls, although it failed
to show any statistical significance. Interestingly, this SNP
has been shown to have a minor allele (A) frequency of 0.05,
which  is  unique  and  found  only  in  sub-Saharan  African
HapMap samples. It is not polymorphic in either Caucasian
or Asian (Chinese or Japanese) HapMap samples. Ayala-Lugo
and colleagues [28] also identified this variant in samples of
African  ancestry  including  African  American,  Ghanaian,
Nigerian, and the Caribbean. They did not find any significant
difference in allele frequency between cases of open-angle
glaucoma and controls with the sample size of 81 patients and
88 controls. Our study has a much larger data set of 140 POAG
TABLE 1. LIST OF PCR PRIMERS FOR OPTN DNA SEQUENCING IN GHANAIAN POAG CASES AND CONTROLS.
OPTN
exon Forward primer sequence Reverse primer sequence
PCR
product
size (bp)
Mg2+ 
concentration
4 TAAGTATTAGCAATCGCCAA AGTGCAAAGGGATGGCATTT 340 2.0 mM
5 CATCAGATCAAGTCCACTTT GGAGTCTAGACACGTAAGAT 340 2.0 mM
6 ATGGTGCCCAGCCTTAGTTT CAATCCTTGGCTTGTGTTGA 340 1.5 mM
7 CATCTGAATGTTTGGAAGCT TATTCTGGAAAGATCCTGGT 340 1.5 mM
8 ATACTGAACAGGGCATTGTC GTGGTTGCACAATCCTGGAA 300 1.5 mM
9 GATCCTTTATCCCAATTGTA TTGAATTCAGTGGCTGGACT 282 2.0 mM
10 TTGATTCACCAGCCAGTCTT GCTCACACATTAACTGGAAC 400 1.5 mM
11 TGCATTCATAAACCCTACAG TAGGACTCCTTCAGATAAGT 400 1.5 mM
12 TTGAGAGTAAGAAATGCTAG GATTTAGTGAAGGATTCATG 340 1.5 mM
13 ATGTTGCCCAGGCTTGTCTC CACCATTGCTTTCCAATGCG 420 1.5 mM
14 GGATACAGCACTACCTCCTC TCAGGAACGTCTTTGGACAG 300 1.5 mM
15 GCTCAGTGTTGTCATGTTTC GGAATCCATTGTAGAGAATG 240 1.5 mM
16 TCGCCATCTGTTCTTCAAGT AAAAGCACAACTCTTGGAGG 269 2.0 mM
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2369cases and 130 controls, all from Accra, Ghana. All the patients
with E322K variants have relative high IOP (>30 mmHg) and
the age-onset ranges from 43 to 85 years old. Both Ayala-
Lugo’s and our studies suggest that E322K variant in OPTN
may not contribute to the increased risk of POAG in the
population of African ancestry.
The M98K OPTN variant is the most common variant
reported in most studies [13,33]. Similar to others, we have
found that the M98K variant is the most prevalent in this
population. The M98K variant was originally described as a
risk-associated alteration for hereditary adult-onset POAG
[6]. This variant has been reported to be a potential risk factor
for NTG or POAG in some Asian populations [6,14,15,27,
34-36]. However, most studies have not found an association
between  this  variant  and  either  NTG  or  POAG  [16-18,
37-42]. Consistent with these studies, we also failed to identify
an  association  of  the  M98K  variant  with  POAG  in  the
Ghanaian population.
Both V147L and A301G variants are novel. Each of them
was found in a single POAG case and none of the controls.
The age-onset for both patients is relatively early (40 and 59
years old). The IOP for these two patients is also relatively
high,  more  than  30  mmHg.  Although  not  statistically
significant, it remains possible that these rare variants might
contribute to the pathogenesis of POAG. Additional studies
in larger data sets will be necessary to corroborate the role of
these OPTN variants in glaucoma. Although we did not find
any significant association between OPTN coding variants
and  Ghanaian  POAG  patients  with  elevated  IOP,  it  is
important to check these variants, especially the novel ones,
in other populations with a large data set and to check their
functional impact with the OPTN protein.
In conclusion, we have identified seven genetic variants
of OPTN of which three are novel in the Ghanaian population.
Two non-synonymous coding variants were found only in
POAG patients and not in controls. The study presented here
is  the  first  large  scale  comprehensive  analysis  of  OPTN
variants in the Ghanaian (West African) POAG patients with
elevated intraocular pressure.
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